Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04014764 · ClinicalTrials.gov registry record
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
A clinical trial of Multiple Myeloma and Lymphoma, sponsored by Notable Labs.
- Completed
- Registry status
- 119
- Enrollment target
- 20
- Study locations
NCT04014764 is a study of Multiple Myeloma and Lymphoma that has completed, run by Notable Labs. The registered enrollment target is 119 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT04014764, a study of Multiple Myeloma and Lymphoma, has completed, sponsored by Notable Labs.
- COMPLETED
- Registry status
- 119 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, multicenter observational study to collect clinically annotated biospecimens in order to assess the correlation between ex vivo data generated by the Notable assay platform and clinical outcome.
Conditions Studied
Interventions
- OTHER This is a non-interventional study
Study Locations (20)
Other
- University Hospital of Alexandroupolis - Alexandroupoli
- National Kapodistrian University of Athens - Athens
- Attikon University Hospital - Athens
- National Kapodistrian Hospital/Laikon General Hospital - Athens
- University Hospital of Ioánnina - Ioannina
- University Hospital Patras - Pátrai
- Hospital General Universitario de Alicante - Alicante
- Hospital San Pedro de Alcántare - Cáceres
- Hospital Universitari I Politècnic La Fe - Valencia
California
- CBCC Global Research - Bakersfield
- Pacific Central Coast Health Centers -- SLO Oncology and Hematology Health Center - San Luis Obispo
Florida
- Ocala Oncology Center - Ocala
- Mid Florida Hematology and Oncology Center - Orange City
Colorado
- Colorado West Healthcare System, dba Grand Valley Oncology - Grand Junction
Louisiana
- Touro Infirmary - New Orleans
Maine
- Northern Light Cancer Care Center - Brewer
New York
- New York Cancer and Blood Specialists - Port Jefferson Station
North Carolina
- East Carolina University - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2019-12-15 |
| Est. Completion | 2022-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04014764
The ClinicalTrials.gov registry entry for NCT04014764 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower). The listed sponsor is Notable Labs, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which This is a non-interventional study is the first listed.
NCT04014764 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04014764 about?
NCT04014764 is a clinical study titled "Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy". This is a prospective, multicenter observational study to collect clinically annotated biospecimens in order to assess the correlation between ex vivo data generated by the Notable assay platform and clinical outcome.
What is the current status of trial NCT04014764?
This trial is currently completed. The enrollment target is 119 participants. The study started on 2019-12-15. Estimated completion is 2022-03-31.
What conditions does trial NCT04014764 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Myeloproliferative Neoplasm.
What interventions are being tested in trial NCT04014764?
The interventions under investigation include: This is a non-interventional study (OTHER).
Who is sponsoring clinical trial NCT04014764?
This trial is sponsored by Notable Labs, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04014764 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Louisiana, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.